

# Biopharmaceutics & Drug Disposition

VOLUME 33 NUMBER 1 JANUARY 2012


## Original Papers

Allometric scaling of biliary clearance  
Desloratadine poor metabolizers in Jordanians  
Altered hepatic metabolism of CYP3A  
substrates in ARF rats

View this journal online at  
[wileyonlinelibrary.com/journal/bdd](http://wileyonlinelibrary.com/journal/bdd)  
ISSN 0142-2782  
BDDID8 33(1) 1-45 (2012)



WILEY-  
BLACKWELL



## Contents

VOLUME 33, ISSUE 1

JANUARY 2012

### ORIGINAL PAPERS

**Interspecies scaling: prediction of human biliary clearance and comparison with QSPKR**

Marilyn E. Morris, Xinning Yang, Yash A. Gandhi, Suraj G. Bhansali, and Lisa J. Benincosa . . . . . 1

**Prevalence of desloratadine poor metabolizer phenotype in healthy Jordanian males**

Nancy Hakooz and Isam I. Salem . . . . . 15

**Comparative study on altered hepatic metabolism of CYP3A substrates in rats with glycerol-induced acute renal failure**

Jun-ichi Kusaba, Noriko Kajikawa, Hiromu Kawasaki, Yuji Kurosaki, and Tetsuya Aiba . . . . . 22

### SHORT COMMUNICATIONS

**Effect of the timing of food intake on the absorption and bioavailability of carbamazepine immediate-release tablets in beagle dogs**

Cai-hong Xu, Gang Cheng, Yi Liu, Ye Tian, Jing Yan, and Mei-juan Zou . . . . . 30

**Mass balance and metabolism of aclidinium bromide following intravenous administration of [<sup>14</sup>C]-aclidinium bromide in healthy subjects**

Stephan Ortiz, Stephen Flach, John Ho, Fanying Li, Cynthia F. Caracta, Esther Garcia Gil, and Josep M. Jansat . . . . . 39





## Contents

VOLUME 33, ISSUE 2

MARCH 2012

Special Issue on Resurgence in the Practical Use of Physiologically-Based Pharmacokinetics (PBPK)  
Allied with *In Vitro In Vivo* Extrapolations (IVIVE) in Drug Development

### EDITORIAL COMMENTARY

#### **Physiologically based pharmacokinetic (PBPK) modeling: It is here to stay!**

Amin Rostami-Hodjegan, Ikumi Tamai and K. Sandy Pang . . . . . 47

### INVITED COMMENTARIES

#### **PBPK as a tool in regulatory review**

Shiew-Mei Huang . . . . . 51

#### **An industrial perspective on contemporary applications of PBPK models in drug discovery and development**

Bill J. Smith . . . . . 53

### REVIEWS

#### **Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?**

François Bouzom, Kathryn Ball, Nathalie Perdaems and Bernard Walther . . . . . 55

#### **Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism-based adverse events**

Christopher L. Shaffer, Renato J. Scialis, Haojing Rong and R. Scott Obach . . . . . 72

#### **Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies**

Yuan Chen, Jin Y. Jin, Sophie Mukadam, Vikram Malhi and Jane R. Kenny . . . . . 85

#### **Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice**

Joseph A. Grillo, Ping Zhao, Julie Bullock, Brian P. Booth, Min Lu, Kathy Robie-Suh, Eva Gil Berglund, K. Sandy Pang, Atiqur Rahman, Lei Zhang, Lawrence J. Lesko and Shiew-Mei Huang . . . . . 99

#### **From preclinical to human – prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example**

Vikash Kumar Sinha, Jan Snoeys, Nancy Van Osselaer, Achiel Van Peer, Claire Mackie and Donald Heald . . . . . 111

## Contents

VOLUME 33, ISSUE 3

APRIL 2012

### ORIGINAL ARTICLES

- Metabolism and excretion studies of oral administered naringin, a putative antitussive, in rats and dogs**  
Menghua Liu, Wei Zou, Cuiping Yang, Wei Peng and Weiwei Su . . . . . 123
- Pharmacokinetics and metabolism of jatrorrhizine, a gastric prokinetic drug candidate**  
Rong Shi, Hui Zhou, Bingliang Ma, Yueming Ma, Dazheng Wu, Xinhong Wang, Hongfeng Luo and Nengneng Cheng . . . . . 135
- A case study on the *in silico* absorption simulations of levothyroxine sodium immediate-release tablets**  
Ivana Kocic, Irena Homsek, Mirjana Dacevic, Sandra Grbic, Jelena Parojcic, Katarina Vucicevic, Milica Prostran and Branislava Miljkovic . . . . . 146
- Pharmacokinetics, distribution and excretion of YM155 monobromide, a novel small-molecule survivin suppressant, in male and pregnant or lactating female rats**  
Tsuyoshi Minematsu, Takuya Sonoda, Tadashi Hashimoto, Megumi Iwai, Todd Oppeneer, Laurie Felder, Nobuaki Shirai, Aiji Miyashita and Takashi Usui . . . . . 160
- Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake**  
Min-Koo Choi and Im-Sook Song . . . . . 170





## Contents

VOLUME 33, ISSUE 4

### ORIGINAL PAPERS

**Predicting human hepatic clearance from *in vitro* drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug–drug interactions**  
Gian Camenisch and Ken-ichi Umehara . . . . . 179

**Investigation of drug–drug interaction *via* mechanism-based inhibition of cytochrome P450 3A by macrolides in dexamethasone-treated female rats**  
Takushi Kanazu, Norihito Sato, Kyoko Kadono, Akira Touchi, Yuri Takeda, Yoshitaka Yamaguchi and Takahiko Baba . . . . . 195

**Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC-MS/MS cocktail assays and RT-PCR**  
Li Liu, Ganesh M. Mugundu, Brian J. Kirby, Divya Samineni, Pankaj B. Desai and Jashvant D. Unadkat . . . . . 207

**Comparative transcutaneous immunization with imiquimod-containing ointments and potential of *in vitro* methods to predict effects**  
Karsten Gogoll, Pamela Stein, Hai Wei, Hansjörg Schild, Markus Radsak and Peter Langguth . . . . . 218

### SHORT COMMUNICATION

**Gender differences in pharmacokinetics of lumefantrine and its metabolite desbutyl-lumefantrine in rats**  
Wahajuddin, Sheelendra Pratap Singh and Girish Kumar Jain . . . . . 229

## Contents

VOLUME 33, ISSUE 5

JULY 2012

### ORIGINAL PAPERS

- Effects of glycyrrhizin on biliary transport and hepatic levels of glutathione in rats**  
Ruijuan Xu, Xueying Zhang, Jin Yang, Xiaoquan Liu, Andrew K. Davey and Jiping Wang . . . . . 235
- Comparison of the intestinal absorption and bioavailability of  $\gamma$ -tocotrienol and  $\alpha$ -tocopherol: *in vitro*, *in situ* and *in vivo* studies**  
Bilal S. Abuasal, Hisham Qosa, Paul W. Sylvester and Amal Kaddoumi . . . . . 246
- Identification of human cytochrome P450 enzymes involved in the metabolism of a novel  $\kappa$ -opioid receptor agonist, nalfurafine hydrochloride**  
Akihiro Ando, Keiyu Oshida, Shinichi Fukuyama, Ayano Watanabe, Hisashi Hashimoto and Yohei Miyamoto . . . . . 257
- Pharmacokinetic profiling of efavirenz–emtricitabine–tenofovir fixed dose combination in pregnant and non-pregnant rats**  
Ramakrishna Nirogi, Gopinadh Bhyrapuneni, Vishwottam Kandikere, Nageswararao Muddana, Ramanatha Saralaya, Prashanth Komarneni, Koteswara Mudigonda and K. Mukkanti . . . . . 265
- SHORT COMMUNICATION**
- Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel**  
Chia-Hao Chen, Jyh-Chin Yang, Yow-Shieng Uang and Chun-Jung Lin . . . . . 278





## Contents

VOLUME 33, ISSUE 6

### ORIGINAL PAPERS

<b>Pharmacokinetics of salsalate and salicylic acid in normal and diabetic rats</b> Yanguang Cao, Debra C. DuBois, Richard R. Almon and William J. Jusko . . . . .	285
<b>Evaluation of pharmacokinetic differences of acetaminophen in pseudo germ-free rats</b> Soo Hyun Lee, Ji Hye An, Hwa Jeong Lee and Byung Hwa Jung . . . . .	292
<b>Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood–brain barrier</b> Yasuhisa Nagasaka, Kazuo Oda, Takafumi Iwatsubo, Akio Kawamura and Takashi Usui . . . . .	304
<b>Effect of pH, mucin and bovine serum on rifampicin permeability through Caco-2 cells</b> José Eduardo Gonçalves, Mariane Ballerini Fernandes, Chang Chiann, Maria Nella Gai, Jacqueline De Souza and Silvia Storpirtis . . . . .	316
<b>Variation in omeprazole pharmacokinetics in a random Iranian population: a pilot study</b> Maryam Noubarani, Farzad Kobarfard, Manijeh Motevalian and Fariborz Keyhanfar . . . . .	324
<b>Active intestinal absorption of fluoroquinolone antibacterial agent ciprofloxacin by organic anion transporting polypeptide, Oatp1a5</b> Hiroshi Arakawa, Yoshiyuki Shirasaka, Makoto Haga, Takeo Nakanishi and Ikumi Tamai . . . . .	332
<b>SHORT COMMUNICATION</b>	
<b>Distribution of CYP2C9*13 allele in the Chinese Han and the long-range haplotype containing CYP2C9*13 and CYP2C19*2</b> Dayong Si, Juan Wang, Yifan Zhang, Dafang Zhong and Hui Zhou . . . . .	342

# Contents

VOLUME 33, ISSUE 7

OCTOBER 2012

Special Issue on Relationships Between *In Vitro* Dissolution and *In Vivo* Response: Part I  
Guest Editors: Peter Langguth and Patrick Marroum

## PREFACE

### Relationships between *in vitro* drug dissolution and *in vivo* response

Peter Langguth and Patrick Marroum . . . . . 347

## ORIGINAL PAPERS

### Development strategies for IVIVC in an industrial environment

Jack A. Cook . . . . . 349

### Integrating drug permeability with dissolution profile to develop IVIVC

Ryusuke Takano, Makoto Kataoka and Shinji Yamashita . . . . . 354

### *In silico* prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen

Yasuhiro Tsume, Peter Langguth, Alfredo Garcia-Arieta and Gordon L. Amidon . . . . . 366

### Mechanistic analysis of solute transport in an *in vitro* physiological two-phase dissolution apparatus

Deanna M. Mudie, Yi Shi, Haili Ping, Ping Gao, Gordon L. Amidon and Gregory E. Amidon . . . . . 378

### Mechanistic investigation of food effect on disintegration and dissolution of BCS class III compound solid formulations: the importance of viscosity

Asma Radwan, Gordon L. Amidon and Peter Langguth . . . . . 403

### *In vivo* predictive release methods for medicated chewing gums

Jayachandar Gajendran, Johannes Kraemer and Peter Langguth . . . . . 417







## Contents

VOLUME 33, ISSUE 8

### ORIGINAL PAPERS

- Enhanced oral bioavailability and anti-tumour effect of paclitaxel by 20(s)-ginsenoside Rg3 *in vivo***  
Lei-Qiong Yang, Bin Wang, Hui Gan, Shou-Ting Fu, Xiao-Xia Zhu, Zhuo-Na Wu, Da-Wei Zhan, Ruo-Lan Gu,  
Gui-Fang Dou and Zhi-Yun Meng . . . . . 425
- In vitro* and *in vivo* evaluation of a primaquine prodrug without red blood cell membrane destabilization property**  
Marcelo Gomes Davanço, Michel Leandro Campos, Marco Antonio Nogueira, Silvio Lopes Campos, Ricardo Vian Marques,  
Jean Leandro dos Santos, Chung Man Chin, Luiz Marcos da Fonseca and Rosângela Gonçalves Peccinini . . . . . 437
- Repeated dosing of piperine induced gene expression of P-glycoprotein via stimulated pregnane-X-receptor activity and altered pharmacokinetics of diltiazem in rats**  
Fu Qiang, Keon-Wook Kang and Hyo-Kyung Han . . . . . 446
- Drug-drug interaction study to assess the effects of atorvastatin co-administration on pharmacokinetics and anti-thrombotic properties of cilostazol in male Wistar rats**  
Rahul Vats, Kanthikiran V. S. Varanasi, Rambabu Arla, Sridhar Veeraraghvan and Shraddha Rajak . . . . . 455
- Identification of CYP isozymes involved in benzbromarone metabolism in human liver microsomes**  
Kaoru Kobayashi, Eri Kajiwara, Masayuki Ishikawa, Hidenobu Oka and Kan Chiba . . . . . 466
- Comparative pharmacokinetic study of paclitaxel and docetaxel in streptozotocin-induced diabetic rats**  
Joo Hyun Lee, Areum Lee, Ju-Hee Oh and Young-Joo Lee . . . . . 474



## Contents

VOLUME 33, ISSUE 9

DECEMBER 2012

### ORIGINAL PAPERS

#### Pharmacokinetic interactions among major bioactive components in *Radix Scutellariae* via metabolic competition

Chen-Rui Li, Li Zhang, Siu-Kwan Wo, Li-Min Zhou, Ge Lin and Zhong Zuo . . . . . 487

#### Pharmacokinetic and safety evaluation of the use of ciprofloxacin on an isoniazid-rifampicin regimen in rabbits

Elias Carvalho Padilha, Rodrigo Vieira Pires, Marco Antonio Ferraz Nogueira Filho, Diego Vinicius de Pontes Machado, Helen Mariana Baldan, Marcelo Gomes Davanço, Michel Leandro Campos, Iguatemy Lourenço Brunetti and Rosângela Gonçalves Peccinini . . . . . 501

#### Understanding pharmacokinetic food effects using molecular dynamics simulation coupled with physiologically based pharmacokinetic modeling

David C. Turner, Fuchang Yin, James T. Kindt and Hailing Zhang . . . . . 510

#### Development of oral extended release formulations of 6-hydroxybuspirone

Sarah J. Nicholson, Peter Timmins, Randy C. Dockens, Alyson Connor, Robert Croop, Peter Ferrie, Jianing Zeng, Andrew B. Dennis and Ian Wilding . . . . . 522

#### Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability

Binfeng Xia, Tycho Heimbach, Handan He and Tsu-han Lin . . . . . 536

#### Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects

Sonja Krösser, Anne Marquet, Dieter Galleman, Peter Wolna, Nicolas Fauchoux, Robert Hermann and Andreas Johne . . . . . 550